These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24628640)

  • 1. Sustained 4-year cognitive and functional response in early Alzheimer's disease with pioglitazone.
    Read S; Wu P; Biscow M
    J Am Geriatr Soc; 2014 Mar; 62(3):584-6. PubMed ID: 24628640
    [No Abstract]   [Full Text] [Related]  

  • 2. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus.
    Hanyu H; Sato T; Kiuchi A; Sakurai H; Iwamoto T
    J Am Geriatr Soc; 2009 Jan; 57(1):177-9. PubMed ID: 19170800
    [No Abstract]   [Full Text] [Related]  

  • 3. Pioglitazone for the treatment of Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease.
    Hanyu H; Sato T; Sakurai H; Iwamoto T
    J Am Geriatr Soc; 2010 May; 58(5):1000-1. PubMed ID: 20722838
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
    Gupta R; Gupta LK
    Pharmacol Biochem Behav; 2012 Aug; 102(2):184-90. PubMed ID: 22503969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice.
    Almasi-Nasrabadi M; Javadi-Paydar M; Mahdavian S; Babaei R; Sharifian M; Norouzi A; Dehpour AR
    Behav Brain Res; 2012 May; 231(1):138-45. PubMed ID: 22440233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Risner ME; Saunders AM; Altman JF; Ormandy GC; Craft S; Foley IM; Zvartau-Hind ME; Hosford DA; Roses AD;
    Pharmacogenomics J; 2006; 6(4):246-54. PubMed ID: 16446752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using genetics to enable studies on the prevention of Alzheimer's disease.
    Crenshaw DG; Gottschalk WK; Lutz MW; Grossman I; Saunders AM; Burke JR; Welsh-Bohmer KA; Brannan SK; Burns DK; Roses AD
    Clin Pharmacol Ther; 2013 Feb; 93(2):177-85. PubMed ID: 23249780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
    Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.
    Baraka A; ElGhotny S
    Eur J Pharmacol; 2010 Sep; 641(2-3):123-7. PubMed ID: 20639139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
    Stein MS; Scherer SC; Ladd KS; Harrison LC
    J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.
    Rodriguez-Rivera J; Denner L; Dineley KT
    Behav Brain Res; 2011 Jan; 216(1):255-61. PubMed ID: 20709114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
    Sato T; Hanyu H; Hirao K; Kanetaka H; Sakurai H; Iwamoto T
    Neurobiol Aging; 2011 Sep; 32(9):1626-33. PubMed ID: 19923038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
    Miller BW; Willett KC; Desilets AR
    Ann Pharmacother; 2011 Nov; 45(11):1416-24. PubMed ID: 22028424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment.
    Molinuevo JL; Berthier ML; Rami L
    Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease.
    Yamada K; Uchida S; Takahashi S; Takayama M; Nagata Y; Suzuki N; Shirakura S; Kanda T
    Brain Res; 2010 Sep; 1352():176-86. PubMed ID: 20627092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired knowledge for fruits and vegetables in semantic dementia.
    Mendez MF
    J Neuropsychiatry Clin Neurosci; 2007; 19(3):349-50. PubMed ID: 17827433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.